Navigation Links
Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
Date:3/22/2012

TARRYTOWN, N.Y., March 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results of the Phase 1 clinical program with their investigational product REGN727/SAR236553, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) were published in the March 22, 2012 issue of the New England Journal of Medicine.  The primary author of the article, entitled "Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol," was Evan A. Stein, M.D., Ph.D., Director of the Metabolic and Atherosclerosis Research Center in Cincinnati, Ohio, and Principal Investigator of one of the REGN727/SAR236553 Phase 1 clinical trials. 

Additionally, results of two of three completed Phase 2 studies of REGN727/SAR236553 will be presented at oral sessions at the American College of Cardiology (ACC) annual meeting.  The presentations are:

  • "A Randomized, Double-Blind, Placebo-Controlled Trial Of The Safety And Efficacy of a Monoclonal Antibody To Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, REGN727/SAR236553, in Patients With Primary Hypercholesterolemia" will be presented by James M. McKenney, Pharm.D, Professor Emeritus, Virginia Commonwealth University School of Medicine, during a Late-Breaking Clinical Trial session on Monday, March 26 at 11:14 AM.
  • "The Effects of Co-administering a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, REGN727/SAR236553, with 10 and 80 mg Atorvastatin Compared to 80 mg Atorvastatin Alone in Patients With Primary Hypercholesterolemia" will be presented by Eli M. Roth, M.D., Professor of Clinical Medicine and Director of Preventive Cardiology for the Division of Cardiology, University of Cincinnati College of Medicine, on Sunday, March 25 a
    '/>"/>

  • SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
    2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
    3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
    4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
    5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
    6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
    7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
    8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
    9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
    10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
    11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015 /PRNewswire/ ... three-dimensional biology company focused on delivering breakthrough 3D ... , President and Chief Executive Officer, will present ... "We invite you to join us for ... to provide updates on our commercial launch of ...
    (Date:2/27/2015)... MINNEAPOLIS , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... develops, manufactures and markets innovative proprietary products to treat ... the 27th Annual ROTH Conference on Tuesday, March 10, ... Brett Reynolds , Chief Financial Officer, will present ... one on one at the conference at the Ritz ...
    (Date:2/27/2015)... Mass. and JERUSALEM , ... biopharma company developing octreotide capsules, its lead product for ... a $70 million Series E financing round. Participants in ... Sofinnova Ventures, and an undisclosed blue chip public investment ... Capital, 7 Med Health Ventures, Abingworth and ARCH Venture ...
    Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
    ... 2011 - Vention Medical, a leading full-service ... acquisition of ANSAmed, Ireland,s premier  provider of ... and multi-lumen extrusion capabilities, and catheter design, ... acquisition of ANSAmed will expand Vention Medical,s ...
    ... 26, 2011 Varian Medical Systems (NYSE: VAR ... with Bank of America, N.A. to repurchase $250 million of ... the company amended its revolving credit facility with Bank of ... to $300 million. Under the accelerated repurchase agreement, ...
    Cached Medicine Technology:Vention Medical Acquires ANSAmed 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3
    (Date:3/1/2015)... ERISAPros is pleased to announce ... the professional staff of its Compliance Department. , Evelyn ... State University-Mortiz College of Law. Prior to joining ERISAPros, ... several Fortune 500 companies as well as several privately ... Her experiences range from benefit plan design, vendor management, ...
    (Date:2/28/2015)... Santa Cruz, california (PRWEB) February 28, 2015 ... an ever growing number of practicing physicians as a way ... experience, training or education regarding Cannabis as medicine. Since the ... have been very few resources available to licensed physicians ... treatment to a patient. Dr. Deborah Malka in Santa ...
    (Date:2/28/2015)... Calgary, AB (PRWEB) February 28, 2015 ... and is now a distributor of the machine. The ... part of their license, like a franchise model. The ... people prevent and reverse heart disease. To buy ... Heart Fit Clinic can help individuals through this process ...
    (Date:2/28/2015)... Indosoft Inc , developers of Q-Suite, ... pleased to announce the development of Q-Suite 5.9. Building ... of Q-Suite, this new version will include enhancements to ... features to the leading edge call center software. General ... add features to enhance security and protection. Administrators will ...
    (Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
    Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
    ... Company) (NYSE: BDX ), a global medical technology company,announced today that ... 2008 Annual Credit Suisse Healthcare Conference ... pm ET, Lazard Capital Markets 5th Annual ... 10:55 a.m. ET, A live webcast of BD,s ...
    ... (human papillomavirus) vaccines and the validation of a simple oral ... studies by a Johns Hopkins Kimmel Cancer Center investigator. , ... identify HPV infection as the cause of certain oral cancers ... risk factor for these cancers, reports her latest work in ...
    ... Taking Medications for Blood Pressure, Cholesterol, ... Asthma, ADD/ADHD, Depression and Diabetes, ST. LOUIS, Nov. 3 ... type 2 diabetes medications between 2002 and,2005, with girls between ... One likely cause: Obesity, which is closely associated with type,2 ...
    ... Declared, ACTON, Mass., Nov. 3 Psychemedics Corporation,(Nasdaq: ... for the,period ended September 30, 2008. The Company also ... shareholders of record as of,December 3, 2008 to be ... 49th consecutive quarterly dividend., The Company,s third quarter ...
    ... Robbins & Myers, Inc.,(NYSE: RBN ) announced ... Conference on November 11, 2008. The Company will be ... and Christopher,M. Hix, Vice President and Chief Financial Officer., ... CST, at,the Four Seasons Hotel in Chicago, Illinois. It ...
    ... Leading Cause of Death in U.S., SWANTON, Vt., ... Month, to help raise awareness about Chronic,Obstructive Pulmonary Disease ... will be making downloadable,tips available to COPD patients on ... November newsletter and blogs to raising awareness,about this 4th ...
    Cached Medicine News:Health News:Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test 2Health News:Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test 3Health News:Tweens and Teens Double Use of Diabetes Drugs 2Health News:Tweens and Teens Double Use of Diabetes Drugs 3Health News:Tweens and Teens Double Use of Diabetes Drugs 4Health News:Psychemedics Corporation Announces Third Quarter Results 2Health News:Psychemedics Corporation Announces Third Quarter Results 3Health News:Psychemedics Corporation Announces Third Quarter Results 4Health News:Psychemedics Corporation Announces Third Quarter Results 5Health News:AllerAir Dedicates November to COPD Awareness Month 2
    ... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
    ... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
    ... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
    ... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
    Medicine Products: